Atara Biotherapeutics (ATRA) Current Assets (2013 - 2026)

Atara Biotherapeutics has reported Current Assets for 14 years, with the latest figure at $12.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 55.22% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (down 55.22% YoY), and the FY2025 full-year result was $12.2 million, down 81.18% from the prior year.
• Current Assets for Q1 2026 stood at $12.2 million, roughly flat from $12.2 million in the prior quarter.
• The five-year high for Current Assets was $347.0 million in Q2 2022, with the low at $12.2 million in Q1 2026.
• Historically, Current Assets has averaged $133.9 million across 5 years, with a median of $101.9 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets slipped 11.56% — and 2025, when it slumped 81.18%.
• Atara Biotherapeutics' Current Assets stood at $295.1 million in 2022, then sank by 65.48% to $101.9 million in 2023, then slumped by 36.3% to $64.9 million in 2024, then tumbled by 81.18% to $12.2 million in 2025, then slipped by 0.32% to $12.2 million in 2026.
• The last three Current Assets figures came in at $12.2 million (Q1 2026), $12.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.